Clinical Policy: Lazertinib (Lazcluze)
Customize your policy alerts
Sign up for Ambetter Nevada Policy CP.PHAR.695 alerts
Get alerted when Policy CP.PHAR.695 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical-necessity coverage for oral lazertinib (Lazcluze) in commercial, marketplace/ICHRA, and Medicaid lines of business. It applies to adult members with recurrent, advanced, or metastatic non-small cell lung cancer and specifies initial- and continued-therapy requirements.
The policy added Lazcluze monotherapy as an allowed treatment option for first-line therapy and continuation therapy after progression in specified asymptomatic or limited-progressive disease settings.
The policy added combination Lazcluze and Rybrevant as subsequent therapy following Tagrisso-based therapy.
The policy added the health insurance marketplace/ICHRA line of business.
Initial approval duration was revised to 12 months.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.